Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EBITDA (2022 - 2025)

Historic EBITDA for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$46.1 million.

  • Axsome Therapeutics' EBITDA rose 2637.17% to -$46.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$212.4 million, marking a year-over-year increase of 3063.07%. This contributed to the annual value of -$280.6 million for FY2024, which is 2102.32% down from last year.
  • Per Axsome Therapeutics' latest filing, its EBITDA stood at -$46.1 million for Q3 2025, which was up 2637.17% from -$36.7 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' EBITDA ranged from a high of -$6.4 million in Q1 2023 and a low of -$98.3 million during Q4 2023
  • For the 4-year period, Axsome Therapeutics' EBITDA averaged around -$55.5 million, with its median value being -$59.9 million (2022).
  • Per our database at Business Quant, Axsome Therapeutics' EBITDA skyrocketed by 8335.29% in 2023 and then tumbled by 95545.97% in 2024.
  • Axsome Therapeutics' EBITDA (Quarter) stood at -$59.9 million in 2022, then plummeted by 64.01% to -$98.3 million in 2023, then increased by 26.11% to -$72.6 million in 2024, then skyrocketed by 36.5% to -$46.1 million in 2025.
  • Its EBITDA was -$46.1 million in Q3 2025, compared to -$36.7 million in Q2 2025 and -$57.0 million in Q1 2025.